Gilead Sciences has agreed to acquire Cell Design Labs Inc. in a transaction valued at $567 million, including the shares of Cell Design Labs held by Kite. Cell Design Labs is a biotechnology company developing CAR-T and T cell receptor (TCR) therapies, a new class of cancer therapies that involve genetically modifying a patient’s own immune cells to better recognize and attack cancer. Gilead gains Cell Design’s custom cell engineering technology that it is currently developing, and its pipel...